Results 131 to 140 of about 1,282 (161)
Some of the next articles are maybe not open access.
2021
Post-transplant lymphoproliferative disorders (PTLDs) are life-threatening complications after hematopoietic stem cell transplantation (HSCT), often associated to Epstein-Barr virus (EBV) infection. Rituximab, reduction of immunosuppression, and EBV-specific cytotoxic T-lymphocyte (CTL) therapy are recommended as first-line therapy, while unselected ...
Patrizia Comoli, Jan Styczynski
openaire +1 more source
Post-transplant lymphoproliferative disorders (PTLDs) are life-threatening complications after hematopoietic stem cell transplantation (HSCT), often associated to Epstein-Barr virus (EBV) infection. Rituximab, reduction of immunosuppression, and EBV-specific cytotoxic T-lymphocyte (CTL) therapy are recommended as first-line therapy, while unselected ...
Patrizia Comoli, Jan Styczynski
openaire +1 more source
Posttransplant Lymphoproliferative Disorders (PTLDs)
2020Posttransplant lymphoproliferative disorders (PTLDs) are lymphoid or plasmacytic proliferations that develop in solid organ, bone marrow, or stem cell allograft recipients in a setting of immunosuppression. PTLDs’ spectrum ranges from usually EBV-driven reactive lymphoid/plasmacytic proliferations to EBV+ or EBV− monoclonal lymphomas or plasmacytic ...
openaire +1 more source
Biomarkers for PTLD diagnosis and therapies
Pediatric Nephrology, 2019Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of lymphoproliferative disorders and is a serious complication of pediatric transplantation. The majority of PTLD are associated with Epstein Barr virus (EBV) and the characteristic EBV+ B cell lymphomas are the leading post-transplant malignancy in children.
openaire +2 more sources
2010
No therapies are based on data from randomized clinical trials Current outcomes are suboptimal, both in adults and children Death is most common in the first year after diagnosis Success of therapy must include evaluation of allograft outcomes Several new therapies have emerged over the last decade including monoclonal antibody ...
openaire +1 more source
No therapies are based on data from randomized clinical trials Current outcomes are suboptimal, both in adults and children Death is most common in the first year after diagnosis Success of therapy must include evaluation of allograft outcomes Several new therapies have emerged over the last decade including monoclonal antibody ...
openaire +1 more source
2010
Several different types of risk factors (host, infectious, transplant immunosuppression) are associated with posttransplant lymphoproliferative disorders (PTLD) development Epstein—Barr virus (EBV) infection is the single most important risk factor PTLD is a significant cause of earlier graft loss and added ...
openaire +1 more source
Several different types of risk factors (host, infectious, transplant immunosuppression) are associated with posttransplant lymphoproliferative disorders (PTLD) development Epstein—Barr virus (EBV) infection is the single most important risk factor PTLD is a significant cause of earlier graft loss and added ...
openaire +1 more source
Definitions and Pathology of PTLD
2021The post-transplant lymphoproliferative disorders (PTLDs) are a spectrum of lymphoid and plasmacytic proliferations that in about 60–80% of cases are associated with the Epstein-Barr virus (EBV). They are categorized into four major categories using the 2016 World Health Organization (WHO) classification.
Steven H. Swerdlow, Steven A. Webber
openaire +1 more source
Prognostic Factors of PTLD after SOT
2021Similar to other B-cell malignancies, the prognosis of post-transplant lymphoproliferative disorders (PTLD) subsequent to solid organ transplantation follows comparable principles. Despite remaining one of the most reliable prognostic systems, the International Prognostic Index does not fully hit the mark in regard to the complexity of PTLD and new ...
Donald E. Tsai, Mitchell E. Hughes
openaire +1 more source
Evolving beyond morphology in pediatric PTLD
Blood, 2023Nader Kim El-Mallawany, Kala Y. Kamdar
openaire +2 more sources
Epidemiology of PTLD After SOT
2021PTLD is a relatively rare but important and feared complication of transplantation. Several different types of risk factors (host, infectious, transplant, immunosuppression) are associated with PTLD development. Epstein-Barr virus infection is the single most important risk factor. PTLD is a significant cause of earlier graft loss and added mortality.
openaire +1 more source
Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD
Springer Seminars in Immunopathology, 1998G, Tosato +5 more
openaire +2 more sources